Obesity - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Obesity - Pipeline Review, H1 2018’, provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Obesity

- The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects

- The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Obesity

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeome Corp

Adocia SAS

Aegis Therapeutics LLC

Amgen Inc

Antag Therapeutics ApS

Aoxing Pharmaceutical Company Inc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

Athersys Inc

Auris Medical ...

Abeome Corp

Adocia SAS

Aegis Therapeutics LLC

Amgen Inc

Antag Therapeutics ApS

Aoxing Pharmaceutical Company Inc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

Athersys Inc

Auris Medical Holding AG

Bial - Portela & Ca SA

Biophytis SA

BioRestorative Therapies Inc

Biozeus

Boehringer Ingelheim GmbH

Braasch Biotech LLC

C3J Therapeutics Inc

Callitas Therapeutics Inc

Carmot Therapeutics Inc

Celon Pharma SA

Chong Kun Dang Pharmaceutical Corp

CohBar Inc

CoMentis Inc

Corcept Therapeutics Inc

Daiichi Sankyo Co Ltd

DiscoveryBiomed Inc

Eisai Co Ltd

Eli Lilly and Co

Eternygen GmbH

Evotec AG

FibroGen Inc

Genmedica Therapeutics SL

Gila Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Glucox Biotech AB

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Hyundai Pharmaceutical Co Ltd

Immungenetics AG

Intarcia Therapeutics Inc

Ionis Pharmaceuticals Inc

Johnson & Johnson

Juno Therapeutics Inc

Kissei Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Leading BioSciences Inc

Magnus Life Ltd

MedImmune LLC

Merck & Co Inc

Naia Ltd

NeuroNano Pharma Inc

NGM Biopharmaceuticals Inc

NIBEC

Nordic Bioscience A/S

Novartis AG

Novo Nordisk AS

ObeTherapy Biotechnology

Omeros Corp

OPKO Biologics Ltd

OPKO Health Inc

Oramed Pharmaceuticals Inc

Palatin Technologies Inc

Peptron Inc

Pfizer Inc

PharmaIN Corp

Poxel SA

ProMetic Life Sciences Inc

Regeneron Pharmaceuticals Inc

Renova Therapeutics Inc

Reviva Pharmaceuticals Inc

Saniona AB

Sanofi

Seres Therapeutics Inc

Shionogi & Co Ltd

Sinil Pharmaceutical Co Ltd

SJT Molecular Research SL

Takeda Pharmaceutical Co Ltd

Toray Industries Inc

Vicore Pharma AB

Viking Therapeutics Inc

Vivus Inc

WhanIn Pharmaceutical Co Ltd

XL-protein GmbH

Yuhan Corp

Yuyu Pharma Inc

Zafgen Inc

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Obesity – Overview 9

Obesity – Therapeutics Development 10

Obesity – Therapeutics Assessment 38

Obesity – ...

Table of Contents

Table of Contents 2

Introduction 8

Obesity – Overview 9

Obesity – Therapeutics Development 10

Obesity – Therapeutics Assessment 38

Obesity – Companies Involved in Therapeutics Development 56

Obesity – Drug Profiles 98

Obesity – Dormant Projects 465

Obesity – Discontinued Products 485

Obesity – Product Development Milestones 489

Appendix 499

List of Tables

List of Tables

Number of Products under Development for Obesity, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Obesity, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Obesity – Pipeline by Abeome Corp, H1 2018

Obesity – Pipeline by Adocia SAS, H1 2018

Obesity – Pipeline by Aegis Therapeutics LLC, H1 2018

Obesity – Pipeline by Amgen Inc, H1 2018

Obesity – Pipeline by Antag Therapeutics ApS, H1 2018

Obesity – Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018

Obesity – Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018

Obesity – Pipeline by AstraZeneca Plc, H1 2018

Obesity – Pipeline by Athersys Inc, H1 2018

Obesity – Pipeline by Auris Medical Holding AG, H1 2018

Obesity – Pipeline by Bial - Portela & Ca SA, H1 2018

Obesity – Pipeline by Biophytis SA, H1 2018

Obesity – Pipeline by BioRestorative Therapies Inc, H1 2018

Obesity – Pipeline by Biozeus, H1 2018

Obesity – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Obesity – Pipeline by Braasch Biotech LLC, H1 2018

Obesity – Pipeline by C3J Therapeutics Inc, H1 2018

Obesity – Pipeline by Callitas Therapeutics Inc, H1 2018

Obesity – Pipeline by Carmot Therapeutics Inc, H1 2018

Obesity – Pipeline by Celon Pharma SA, H1 2018

Obesity – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Obesity – Pipeline by CohBar Inc, H1 2018

Obesity – Pipeline by CoMentis Inc, H1 2018

Obesity – Pipeline by Corcept Therapeutics Inc, H1 2018

Obesity – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Obesity – Pipeline by DiscoveryBiomed Inc, H1 2018

Obesity – Pipeline by Eisai Co Ltd, H1 2018

Obesity – Pipeline by Eli Lilly and Co, H1 2018

Obesity – Pipeline by Eternygen GmbH, H1 2018

Obesity – Pipeline by Evotec AG, H1 2018

Obesity – Pipeline by FibroGen Inc, H1 2018

Obesity – Pipeline by Genmedica Therapeutics SL, H1 2018

Obesity – Pipeline by Gila Therapeutics Inc, H1 2018

Obesity – Pipeline by Gilead Sciences Inc, H1 2018

Obesity – Pipeline by GlaxoSmithKline Plc, H1 2018

Obesity – Pipeline by Glucox Biotech AB, H1 2018

Obesity – Pipeline by HanAll Biopharma Co Ltd, H1 2018

Obesity – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Obesity – Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018

Obesity – Pipeline by Immungenetics AG, H1 2018

Obesity – Pipeline by Intarcia Therapeutics Inc, H1 2018

Obesity – Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Obesity – Pipeline by Johnson & Johnson, H1 2018

Obesity – Pipeline by Juno Therapeutics Inc, H1 2018

Obesity – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Obesity – Pipeline by Lead Discovery Center GmbH, H1 2018

Obesity – Pipeline by Leading BioSciences Inc, H1 2018

Obesity – Pipeline by Magnus Life Ltd, H1 2018

Obesity – Pipeline by MedImmune LLC, H1 2018

Obesity – Pipeline by Merck & Co Inc, H1 2018

Obesity – Pipeline by Naia Ltd, H1 2018

List of Figures

List of Figures

Number of Products under Development for Obesity, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Obesity, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports